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O. Janssen et al. / JAMDA 21 (2020) 1102e1107 1103Design: Longitudinal retrospective study using routinely recorded general practice electronic health re-
cords linked with population-based healthcare and mortality data.
Setting and participants: In total, 11,012 community-dwelling persons who received an incident dementia
diagnosis and were listed in a Dutch general practitioner database from 448 general practices in the
Netherlands.
Methods: Using multistate modeling analyses, we estimated the mean duration of care types (no/home/
institutional care) for different ages based on simulations of transition rates and examined the influence
of demographic and clinical factors on these durations.
Results: From dementia diagnosis onward in 85-year-old men, the mean duration without formal care
was 0.7 years, of home care 1.7, and institutional care 1.1 years. In 85-year-old women, the duration
without formal care was 0.8 years, of home care 2.3, and institutional care 2.3 years. Total care duration
was 3.5 years in 85-year-old men and 5.4 years in 85-year-old women. In men, the duration of home care
was longer compared with no formal care and institutional care. The duration of no formal care was
longer in persons not living alone, without prescribed dementia medication, with a non‒Western
migration background, or with a higher income. The duration of home or institutional care was longer in
women, persons without polypharmacy, in those living alone, or those with a Western background.
Conclusions and implications: Our findings help to increase understanding of long-term dementia care
trajectories and show that demographic and clinical factors determine the duration of care types. Our
results can contribute to the organization of healthcare resource planning and monitoring of the effects
of healthcare policy and interventions.
 2020 AMDA e The Society for Post-Acute and Long-Term Care Medicine.Dementia is a long-duration disease and provides a major burden
to the patient, caregiver, and healthcare system. The dependency on
care and care type needed changes with disease progression.1 To aid
healthcare resource planning, it is necessary to understand care
duration and factors that determine care use such as demographic and
health-related factors and migration background.
Formal dementia care consists of home care and institutional care.
Previous studies on dementia care duration focused on duration from
diagnosis to institutionalization2 and from diagnosis to death but did
not distinguish between home and institutional care duration.3
Furthermore, there is limited information on the duration after diag-
nosis without home or institutional care. Previous studies on care use
also had small sample sizes,4,5 includedmemory clinicebased samples
that are less representative of the general population,6,7 did not link
dementia duration to formal care resource data,4,8 or had a short
follow-up time.6
Moreover, little is known about factors affecting care-type dura-
tion. One study showed that older age and male sex were associated
with shorter time of home care,6 and living alone was associated with
a greater institutionalization risk in men compared with women.9
Dementia medication use postponed time to institutionalization9
but did not influence institutional care duration.10 Lower concomi-
tant medication use was associated with longer dementia duration.11
Previous studies indicated that minority ethnic groups tend to access
care services later in the disease,12 and cultural differences in informal
caregiving likely influence formal care use.13
We aimed to investigate the duration of different formal care types
defined as no formal care, home care, and institutional care in persons
with a dementia diagnosis recorded in routine general practitioner
(GP) electronic health records (EHRs) in the Netherlands. We exam-
ined age, sex, living situation, polypharmacy, dementia medication,
migration background, and income effects on care transitions and
duration.
Methods
Data Sources
Patient selection
The Netherlands Institute for Health Services Research Primary
Care Database (NIVEL-PCD) includes routinely recorded care data,pseudonymized at source, from 1.7 million patients from a sample
representative of Dutch general practices (10%).14 Every person
living in the Netherlands is registered at a general practice, and GPs
act as gatekeepers to specialized care. Diagnoses assessed by
medical specialists are copied into the GP EHR system, using the
International Classification of Primary Care (version 1).15 We
included 11,012 community-dwelling persons born before 1965
with an incident International Classification of Primary Care diag-
nosis code P70 (dementia diagnosis) in the NIVEL-PCD from 2008 to
2014. We excluded patients with Down syndrome and patients who
could not be linked to the administrative data sources (n ¼ 1766,
see below).
Administrative data sources
Information on demographics, formal care, medication pre-
scriptions, and death was derived from administrative data sources at
Statistics Netherlands.16 Demographics and death dates were taken
from the Dutch population registry. Living situation was extracted
from the system of social-statistical household composition registry.
Medication use was extracted from the GP EHR and National
Healthcare Institute database at Statistics Netherlands. Net annual
household income corrected for household size, and composition was
derived from the administrative household income registry (available
for N ¼ 10,979). Health resource utilization statistics were taken from
insurance data from the Dutch Central Administration Office database.
Care use registrations were followed up from diagnosis until the end
of 2014.
Dementia Care States
We developed a model containing 3 care states and death as end
stage: (1) no formal care, (2) home care, and (3) institutional care
(Supplementary Figure 1). No formal carewas defined as not receiving
any registered form of care except regular GP care. Home care was
defined as domestic assistance, personal care for activities of daily
living, home nursing support (including palliative care received at
home), day care (included since 2011), or any combination thereof for
at least 30 days. Institutional care was defined as receiving residential
care in a nursing home, residential home, or psychiatric home,
including palliative care received within an institution, for at least
30 days.
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Predictors included baseline age, sex, living situation, poly-
pharmacy, dementia medication, migration background, and socio-
economic status. Living situation was defined as living alone or living
together with another person. Dementia medication ATC4 code N06D
prescriptions were included. Polypharmacy was defined as 5 or more
medication group prescriptions.17 Migration background was divided
in a non‒Western migration background group (Surinamese, Antil-
lean, Aruban, Moroccan, Turkish, or other non‒Western migration
background) and a Western background group (all other persons). For
socioeconomic status, we used a median split to dichotomize income
as more or less than V19,069.Statistical Analyses
For descriptive analyses, we defined 4 age groups: 45‒70, 70‒
80, 80‒90, and 90‒100 years of age. We used a multistate modeling
approach to estimate transition rates and estimated and extrapo-
lated the mean time of a person in each care state.18,19 This
approach incorporates the complete care trajectory and considers
all transitions simultaneously, thereby providing an advantage over
separate survival models for each transition.20 We used the msm R
package (Christopher Jackson, https://github.com/chjackson/msm)
to develop a continuous-time illness-to-death model with age
centered at the sample mean age of 80 years as time scale.18 For
each demographical or health-related factor, we computed hazard
ratios (HRs) for the different transition rates. First, we fitted a
model containing age and sex only (model 1). Next, we extended
the model with polypharmacy, dementia medication, and living
situation (model 2). Then, migration background and income ef-
fects on dementia care transition rates were tested with models
including only age and sex (model 3 and 4, respectively), because
the prevalence of a non‒Western migration background was low
and income was only available for a subgroup. We used the Esti-
mation of Life Expectancies using Continuous-Time multistate
survival models’ package in R19 to estimate duration of care statesTable 1
Sample Characteristics
Baseline Characteristics 45‒70 y n ¼ 1040 7
Age, y mean (SD) 62.4 (4.9) 7
Women, % 49 5
Polypharmacy, % 57 7
Living alone, % 21 3
Prescribed dementia medication, % 16 1
Non‒Western migration background, % 9
Higher income,* % 58 5
Home care, % 14 2
During follow-up
Mean follow-up time, y 3.1
No formal care use beside GP care, % 47 2
Home care, % 51 7
Institutional care, % 17 2
Mortality, % 13 2
Number of care transitions,y %
0 transitions 53 3
1 transition 23 3
2 transitions 15 2
3 or more transitions 9 1
SD, standard deviation.
Characteristics are shown for persons with dementia across different age groups: 45‒70
*Income was available for 10.979 persons.
yNumber of care transitions including transitions from transient states back to less caand demographics and health-related factor effects on estimated
care state duration.
Model Performance
To internally validate our dementia care model, we compared
observed with expected year-specific prevalence estimates
(Supplementary Figure 2). The difference between observed and
predicted values was less than 10% in 71% of comparisons. Mortality
was overestimated (11.4% after 3 years to 13.9% after 6 years) and
home care was underestimated (10.5% after 4 years to 16.7% after
6 years).
Results
Sample Characteristics
In our sample of 11,012 persons with dementia, baseline age was
79.8 (SD 8.0) years and 61% were women. Sample characteristics by
age groups are shown in Table 1. Mean follow-up time was 1.9‒
3.1 years. With increasing age, the relative proportion of women,
persons living alone, and persons with polypharmacy increased. Per-
sons with dementia in the oldest age group receivedw4.5 times more
often home care during diagnosis than the youngest age group. During
follow-up, the proportion of persons receiving home care and insti-
tutional care increased as expected. Mortality during follow-up
increased from 13% in the group age 45‒70 years to 45% in the oldest
group.
Care Transition Rates
Higher age was associated with higher probabilities of mor-
tality and transitions to more care-intensive states. Men had a
lower probability (HR 0.92) of transitioning from no formal care
to home care and a higher probability of mortality when receiving
home care (HR 2.16) or institutional care (HR 1.84) compared with
women. Table 2 shows all care transition rates and HRs of de-
mographic and health-related factors on each care transition.0‒80 y n ¼ 3471 80‒90 y n ¼ 5423 90‒100 y n ¼ 1078
4.9 (2.8) 83.6 (2.7) 91.9 (2.3)
5 64 71
0 75 73
3 52 70
7 12 6
4.5 1.6 1.2
2 51 48
8 51 67
3.0 2.6 1.9
7 14 10
0 83 88
8 34 34
0 32 45
9 37 44
1 37 39
0 16 11
0 9 6
, 70‒80, 80‒90, and 90‒100 years.
re-intensive transient states, excluding transitions to death.
Table 2
Transition Rates and HRs for the Different Demographic Factors and Health-Related Factors on Each Dementia Care Transition
No Formal
Care to
Home Care
No Formal
Care to
Institutional
Care
No Formal
Care
to Death
Home Care
to No
Formal
Care
Home Care
to Institutional
Care
Home Care to
Death
Institutional
Care to No
Formal Care
Institutional
Care to
Home Care
Institutional
Care to Death
Model 1 e Age, sex
Baseline transition rate, at age 80 y 0.43 0.05 0.04 0.20 0.22 0.05 0.07 0.02 0.20
HR age, per 1-y increase 1.04** 1.05** 1.12** 0.98** 1.03** 1.07** 0.97** 0.96** 1.04**
HR male sex 0.92* 0.93 1.07 1.16** 1.05 2.16** 1.10 1.41 1.84**
Model 2 e Age, sex, polypharmacy, living situation, dementia medication
Baseline transition rate, at age 80 y 0.37 0.04 0.03 0.22 0.26 0.05 0.04 0.03 0.22
HR age, per 1-y increase 1.03** 1.05** 1.11** 0.98** 1.03** 1.07** 0.97** 0.97* 1.04**
HR male sex 0.95 1.04 1.27* 1.08 1.02 1.9** 1.02 1.14 1.69**
HR polypharmacy 1.08* 1.00 1.48** 1.02 0.87** 1.39** 1.97** 1.33 1.01
HR living alone 1.15** 1.43** 1.62** 0.80** 0.90* 0.72** 0.83 0.50** 0.80**
HR dementia medication 1.23** 1.27 1.00 0.96 1.15* 0.78* 1.01 0.73 1.03
Model 3 e Age, sex, migration background
Baseline transition rate, at age 80 y 0.33 0.04 0.07 0.30 0.12 0.04 0.15 0.02 0.16
HR age, per 1-y increase 1.04** 1.05** 1.12** 0.98** 1.02** 1.07** 0.97** 0.96** 1.04**
HR male sex 0.91** 0.93 1.07 1.15** 1.06 2.16** 1.10 1.41 1.84**
HR Western migration background 1.31** 1.17 0.66* 0.63** 1.86** 1.21 0.38** 0.98 1.20
Model 4 e Age, sex, income
Baseline transition rate, at age 80 y 0.45 0.05 0.05 0.19 0.23 0.05 0.05 0.02 0.20
HR age, per 1-y increase 1.04** 1.05** 1.12** 0.98** 1.03** 1.07** 0.97** 0.96** 1.04**
HR male sex 0.92** 0.95 1.09 1.15** 1.06 2.13** 1.07 1.37 1.84**
HR higher income 0.89** 0.69** 0.76** 1.12** 0.97 1.11 1.55** 1.55* 0.95
Reported results are baseline transition rates and HRs of the different factors, derived from a multistate Markov model that included 4 states: GP care only, home care,
institutional care and deceased. Baseline transition rates and HRs are shown for model 1 including age and sex, model 2 including age, sex, polypharmacy, living situation, and
dementia medication, model 3 including age, sex, and migration background and model 4 including age, sex, and income.
*P < .05 or **P < .001 indicates HRs that are significantly increased (>1) or decreased (<1). Associated 95% confidence intervals are provided in Supplementary Table 1.
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Table 1.Dementia Care Duration
Figure 1 (Supplementary Table 2) shows the estimated duration of
care types for men and women of different ages. From diagnosis on-
wards, mean duration without formal care at age 85 was 0.7 years in
men and 0.8 years inwomen, home care durationwas 1.7 years inmen
and 2.3 years in women, and institutional care duration was 1.1 years
in men and 2.3 years in women. With increasing age in both men andFig. 1. Estimated duration of dementia care types in years, separately for men and women o
from diagnosis of dementia. Estimated duration for men and women age 65, 75, 85, and 95 ye
in bold.women, the durationwithout formal care became shorter, while home
care and institutional care became longer. Home and institutional care
duration was longer in women compared with men. In men, home
care duration was relatively long. In women, the duration without
formal care was relatively short.
The influence of polypharmacy, living situation, and dementia
medication on the estimated duration of care types is shown in
Supplementary Table 3. Persons without polypharmacy had a
longer institutional care and total duration compared with per-
sons with polypharmacy. Persons living alone had a shorter
duration without formal care than persons not living alone.f age 65, 75, 85, and 95 years. Bars represent estimated dementia care duration in years
ars at time of diagnosis is shown for the different care states. Total durations are shown
O. Janssen et al. / JAMDA 21 (2020) 1102e11071106Persons without prescribed dementia medication had a longer
duration without formal care compared to persons with dementia
medication.
Persons with a non‒Western migration background had a longer
duration without formal care, but a shorter institutional care duration
while total care duration was longer compared with persons with a
Western background (Supplementary Table 4). Persons with a higher
income had a longer duration without formal care and a longer total
duration compared with persons with a lower income
(Supplementary Table 4).
Discussion
The present study describes the duration of different formal care
types and the influence of demographic and clinical characteristics on
care duration in a large sample of persons with dementia in the
Netherlands. Our total dementia care duration of 6.1‒8.5 years in
75-year-olds is in accordance with a retrospective medical records
study.5 However, a previous primary care study found a shorter total
estimated dementia duration in 65-year-olds compared with our
study (6.7 years in persons age 60‒69 vs 10.2 and 13.2 years for 65-
year-old men and women, respectively).8 This could partly be
explained by differences in statistical approach (survival analysis vs
multistate modeling), setting and care system, or assessment time
(1990‒2007 vs 2008‒2014). Interestingly, our care duration estimates
in persons with dementia (ie, remaining life-expectancy from diag-
nosis onwards) are shorter than life-expectancies in the general Dutch
population21 (Supplementary Figure 3).
Several factors influenced the duration of formal care types. In
accordance with most previous studies, older age and male sex were
associated with shorter total care duration.22‒25 Presumably, this
shorter duration in older men can be explained by a shorter life ex-
pectancy in men compared with women.3 Total care duration (ie,
survival from diagnosis onwards) was shortest in persons with poly-
pharmacy, which fits with associations of polypharmacy with more
extensive care dependency and frailty.26,27 Living alonewas associated
with a shorter duration without formal care and longer home and
institutional care duration, and longer total duration, which is in
accordance with previous studies and might be explained by a lack of
informal caregiving at home and resulting in increased use of formal
services in persons living alone.28,29 This underscores the importance
of social support networks for persons living with dementia. Pre-
scribed dementia medication was associated with a shorter duration
without formal care and overall duration. This is inconsistent with
previous results indicating a dose-dependent relationship between
dementia medication and home care amount30 or postponed insti-
tutional care,9 but is consistent with other studies where institutional
care durationwas not influenced by dementia medication.10 Dementia
medication prescription and reimbursement in the Netherlands is
dependent on dementia severity,31 and our results might have been
influenced by differing dementia severity in persons with andwithout
dementia medication. The longer duration without formal care in
persons with a non‒Western migration background might be
explained by an influence of cultural differences in informal family
caregiving on formal healthcare use.13,32 Higher income was associ-
ated with a longer duration without formal care, which is in line with
previously reported associations of lower income with poorer health
status and, thus, increased formal care needs.33 However, lower in-
come has also been identified as a barrier to institutionalization,34 and
access to care may be of influence.
Strengths and Limitations
The present study has several strengths. To the best of our
knowledge, this is the first study on formal care duration and itsdeterminants across the full dementia care trajectory from diagnosis
to death in a registry-based sample. By using long-term information of
a large population of patients from a broad GP sample in combination
with nationwide registries, we have been able to estimate the duration
of care types and the role of potential factors of influence reliably, and
to minimize potential selection and attrition biases.
This study also has limitations. As is typically the case in data
registries, no information was available on dementia severity, de-
mentia subtype, informal care use, need for care, and indication for
care use. Results may be applicable only in the Netherlands because of
differences in care organization, capacity, and access. However, the
impact of most of our predictors on care duration may be similar
across care systems. Furthermore, we included patients with a de-
mentia diagnosis recorded by their GP, and underreporting is possible.
A dementia diagnosis may not have been recorded in some patients
when other diagnoses were considered of greater importance and for
persons with uncertain mild dementia. This potential underreporting
might have resulted in fewer mild dementia cases in our sample and
overestimation of care use. Alternatively, this might have resulted in
increased frailty and comorbidities and underestimation of care use.
This makes it difficult to estimate the impact of this underreporting.
However, we did incorporate knowledge on data quality within the
registry as well as data-recording setting,35 and the registry is
increasingly used for communication between healthcare pro-
fessionals and for patient management.36 Because day care use was
not registered before 2011, home care may have been underreported
before 2011. However, the number of persons receiving only day care,
without additional home care types, was small (approximately 2% per
year). Also, we included baseline health-related factors, and future
studies should incorporate these characteristics as time-varying fac-
tors. Furthermore, palliative care impact on care trajectories could not
be assessed due to limited information in the registry. Palliative care is
registered since 2011 as a separate institutional care type and, because
it was provided to a very small proportion of all registrations between
2011 and 2014, we expect its impact to be limited. Also, age was used
as a time-scale to account for progression risk changes with age, but
possible nonlinear age effects were not addressed.Conclusions and Implications
Our findings increase understanding of long-term dementia care
trajectories and show that the duration without formal care was
longer in persons not living alone, without prescribed dementia
medication, with a non‒Western migration background, or with a
higher income. Home or institutional care duration was longer in
women, persons without polypharmacy, in those living alone, or those
with a Western background. Our results demonstrate the value of
unbiased, real-life care trajectories for visualizing individual variations
and are thus important for healthcare policy decisions. Our estimates
of the duration of different care types could help healthcare pro-
fessionals to provide a prognosis of the care trajectory, which might
aid timely care planning. Furthermore, our insights regarding care
transitions could be valuable for policymakers in examining potential
care organization improvements. As clinical practice is moving to-
wards a more personalized approach, future studies should investi-
gate how informal care, access to care, social support networks,
psychological needs, dementia severity and subtype, and underlying
pathology could further contribute to care duration.Supplementary Data
Supplementary Data related to this article can be found online at
https://doi.org/10.1016/j.jamda.2020.01.008.
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Supplementary Fig. 1. Visual representation of the dementia care multistate model
with 3 transient states and death as end state. Arrows showing transitions between
states, including transitions from transient states back to less severe transient states.
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Supplementary Fig. 2. Comparison of observed and expected year‒specific prevalence of the different care states. Year‒specific prevalence estimates of each care state generated
from multistate model including age and sex compared to observed year‒specific prevalence of each care state in the study sample. Results are shown for an 80‒year‒old person.
Estimates for the different states (no formal care, home care, institutional care and deceased) are shown in percentages for each year up to 6 years.
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Supplementary Fig. 3. Comparison of estimated care durations in years in persons
with dementia with life expectancies in the general Dutch population of men and
women of different ages. Durations in years are shown for men and women age 65, 75,
85, and 95 years. Life expectancy estimates of the general Dutch population were
obtained from CBS Statline calculations from 2014. CBS, Statistics Netherlands.
Supplementary Table 1
95% Confidence Intervals for Transition Rates and HRs for the Different Demographic Factors and Health‒Related Factors on Each Care Transition in Persons With Dementia
No Formal Care
to Home Care
No Formal
Care to
Institutional
Care
No Formal
Care to Death
Home Care
to No Formal
Care
Home
Care to
Institutional
Care
Home
Care to
Death
Institutional
Care to No
Formal Care
Institutional
Care to Home
Care
Institutional
Care to Death
Model 1 e Age, sex
Baseline transition rate,
at age 80 y
0.41‒0.44 0.04‒0.05 0.04‒0.05 0.19‒0.21 0.21‒0.24 0.05‒0.06 0.05‒0.07 0.02‒0.03 0.18‒0.21
HR age, per 1‒y increase 1.03‒1.04 1.04‒1.06 1.11‒1.13 0.98‒0.98 1.02‒1.03 1.06‒1.08 0.95‒0.99 0.94‒0.99 1.03‒1.05
HR male sex 0.86‒0.97 0.78‒1.10 0.91‒1.25 1.07‒1.26 0.98‒1.14 1.92‒2.43 0.98‒1.43 0.93‒2.13 1.65‒2.06
Model 2 e Age, sex, polypharmacy, living situation, dementia medication
Baseline transition
rate, at age 80y
0.35‒0.39 0.03‒0.05 0.02‒0.03 0.20‒0.24 0.24‒0.28 0.04‒0.06 0.03‒0.06 0.02‒0.04 0.19‒0.25
HR age, per 1‒y increase 1.03‒1.04 1.04‒1.06 1.10‒1.12 0.98‒0.99 1.02‒1.03 1.06‒1.09 0.95‒0.99 0.94‒0.99 1.03‒1.05
HR male sex 0.89‒1.01 0.86‒1.26 1.07‒1.17 0.99‒1.17 0.94‒1.11 1.67‒2.15 0.78‒1.34 0.74‒1.76 1.50‒1.91
HR polypharmacy 1.01‒1.15 0.84‒1.20 1.23‒1.77 0.93‒1.11 0.80‒0.94 1.20‒1.61 1.43‒2.71 0.83‒2.12 0.89‒1.14
HR living alone 1.08‒1.23 1.18‒1.73 1.36‒1.93 0.73‒0.87 0.84‒0.98 0.63‒0.81 0.64‒1.08 0.32‒0.79 0.80‒0.90
HR dementia medication 1.14‒1.33 1.00‒1.61 0.78‒1.28 0.86‒1.08 1.04‒1.27 0.64‒0.95 0.73‒1.39 0.40‒1.31 0.88‒1.20
Model 3 e Age, sex, migration background
Baseline transition
rate, at age 80 y
0.28‒0.39 0.02‒0.06 0.05‒0.10 0.25‒0.37 0.09‒0.17 0.03‒0.07 0.09‒0.27 0.01‒0.08 0.10‒0.27
HR age, per 1‒year increase 1.03‒1.04 1.04‒1.06 1.11‒1.13 0.98‒0.99 1.02‒1.03 1.06‒1.08 0.96‒0.99 0.94‒0.99 1.03‒1.05
HR male sex 0.86‒0.97 0.78‒1.10 0.91‒1.25 1.06‒1.25 0.98‒1.14 1.92‒2.43 0.85‒1.43 0.93‒2.14 1.65‒2.06
HR Western migration
background
1.11‒1.53 0.73‒1.87 0.46‒0.94 0.52‒0.76 1.35‒2.55 0.76‒1.92 0.22‒0.68 0.24‒4.05 0.71‒2.04
Model 4 e Age, sex, income
Baseline transition
rate, at age 80 y
0.43‒0.47 0.05‒0.06 0.04‒0.06 0.17‒0.20 0.21‒0.24 0.04‒0.06 0.04‒0.06 0.01‒0.02 0.18‒1.04
HR age, per 1‒year
increase
1.03‒1.04 1.04‒1.06 1.10‒1.13 0.97‒0.98 1.02‒1.03 1.06‒1.08 0.95‒0.99 0.94‒0.99 1.03‒1.05
HR male sex 0.87‒0.97 0.80‒1.13 0.93‒1.28 1.06‒1.24 0.98‒1.14 1.89‒2.40 0.82‒1.38 0.90‒2.07 1.65‒2.06
HR higher income 0.85‒0.95 0.58‒0.82 0.65‒0.89 1.04‒1.21 0.90‒1.04 0.98‒1.25 1.21‒1.98 1.03‒2.33 0.85‒1.07
Reported results are 95% confidence intervals based on standard deviations of baseline transition rates and HRs of the different factors, derived from a multistate Markov
model that included 4 states: GP care only, home care, institutional care and deceased. 95% confidence intervals of baseline transition rates and HRs are shown for model 1
including age and sex, model 2 including age, sex, polypharmacy, living situation, and dementia medication, model 3 including age, sex, and migration background and model
4 including age, sex, and income.
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Supplementary Table 2
Estimated Dementia Care Durations in Years for Men and Women of Different Ages
Age No Formal Care Home Care Institutional Care Total Duration
Male
65 y 4.4 (4.1‒4.7) 3.7 (3.4‒3.9)* 2.2 (1.9‒2.4)* 10.2 (9.7‒10.7)*
75 y 1.9 (1.8‒2.0) 2.6 (2.4‒2.7)* 1.6 (1.5‒1.8)* 6.1 (5.9‒6.4)*
85 y 0.7 (0.7‒0.8) 1.7 (1.6‒1.8)* 1.1 (1.0‒1.2)* 3.5 (3.4‒3.7)*
95 y 0.2 (0.2‒0.3) 1.0 (0.9‒1.1)* 0.7 (0.6‒0.8)* 2.0 (1.8‒2.2)*
Female
65 y 4.4 (4.1‒4.7) 4.7 (4.4‒5.0)* 4.1 (3.7‒4.4)* 13.2 (12.6‒13.8)*
75 y 2.0 (1.9‒2.1) 3.4 (3.3‒3.5)* 3.2 (3.0‒3.4)* 8.5 (8.2‒8.8)*
85 y 0.8 (0.7‒0.8) 2.3 (2.2‒2.4)* 2.3 (2.1‒2.5)* 5.4 (5.2‒5.7)*
95 y 0.2 (0.2‒0.3) 1.0 (0.9‒1.1)* 0.7 (0.6‒0.8)* 2.0 (1.8‒2.2)*
Results are estimated durations of dementia care in years with 95% confidence intervals based on standard deviations of estimated durations. Estimated durations for men and
women age 65, 75, 85, and 95 years at time of diagnosis are shown for the different care states as well as total duration.
*P < .001 indicates different duration estimates from estimates of women.
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Supplementary Table 3
Estimated Dementia Care Durations in Years by (A) Polypharmacy, (B) Living Situation, and (C) Dementia Medication, for Men and Women of Different Ages
(A) Polypharmacy No Formal Care Home Care Institutional Care Total Duration
Male, age
65 y
Polypharmacy 4.6 (4.3‒5.0) 3.7 (3.4‒3.9) 1.9 (1.7‒2.1)* 10.2 (9.6‒10.7)
No polypharmacy 4.6 (4.2‒5.1) 3.4 (3.2‒3.7) 2.4 (2.1‒2.7) 10.4 (9.7‒11.1)
75 y
Polypharmacy 2.0 (1.9‒2.2) 2.5 (2.4‒2.7) 1.4 (1.3‒1.5)* 6.0 (5.7‒6.2)
No polypharmacy 2.1 (1.9‒2.3) 2.4 (2.3‒2.6) 1.7 (1.6‒2.0) 6.3 (5.9‒6.7)
85 y
Polypharmacy 0.8 (0.7‒0.9) 1.6 (1.5‒1.7) 1.0 (0.9‒1.1)* 3.3 (3.1‒3.5)*
No polypharmacy 0.8 (0.8‒0.9) 1.6 (1.5‒1.8) 1.2 (1.0‒1.4) 3.7 (3.4‒4.0)
95 y
Polypharmacy 0.3 (0.2‒0.3) 0.9 (0.8‒1.0) 0.6 (0.5‒0.7) 1.8 (1.6‒1.9)*
No polypharmacy 0.3 (0.3‒0.4) 1.0 (0.9‒1.1) 0.8 (0.6‒0.9) 2.1 (1.8‒2.3)
Female, age
65 y
Polypharmacy 5.0 (4.6‒5.5) 4.7 (4.3‒5.1) 3.3 (2.9‒3.6)* 13.0 (12.3‒13.7)
No polypharmacy 4.8 (4.3‒5.3) 4.1 (3.8‒4.6) 4.0 (3.5‒4.6) 12.9 (12.2‒13.8)
75 y
Polypharmacy 2.3 (2.2‒2.5) 3.3 (3.1‒3.5) 2.6 (2.3‒2.8)* 8.1 (7.7‒8.6)
No polypharmacy 2.2 (2.0‒2.5) 3.0 (2.8‒3.2) 3.1 (2.7‒3.5) 8.3 (7.8‒8.9)
85 y
Polypharmacy 0.9 (0.9‒1.0) 2.1 (2.0‒2.3) 1.8 (1.6‒2.0)* 4.9 (4.6‒5.2)
No polypharmacy 0.9 (0.9‒1.1) 2.0 (1.9‒2.2) 2.2 (1.9‒2.5) 5.2 (4.8‒5.6)
95 y
Polypharmacy 0.3 (0.3‒0.4) 1.3 (1.2‒1.5) 1.2 (1.0‒1.4) 2.9 (2.6‒3.2)
No polypharmacy 0.4 (0.3‒0.4) 1.3 (1.2‒1.5) 1.5 (1.2‒1.8) 3.2 (2.9‒3.5)
(B) Living Situation No formal care Home care Institutional care Total duration
Male, age
65 y
Living alone 3.6 (3.2‒4.0)** 3.8 (3.5‒4.2) 3.1 (2.6‒3.6)* 10.5 (9.8‒11.3)
Not living alone 4.6 (4.2‒5.0) 3.4 (3.2‒3.7) 2.4 (2.0‒2.7) 10.4 (9.7‒11.0)
75 y
Living alone 1.6 (1.5‒1.8)** 2.8 (2.5‒3.0)* 2.3 (2.0‒2.6)* 6.6 (6.2‒7.1)
Not living alone 2.1 (1.9‒2.3) 2.4 (2.3‒2.6) 1.7 (1.6‒2.0) 6.3 (5.9‒6.7)
85 y
Living alone 0.6 (0.6‒0.7)** 1.9 (1.7‒2.1)* 1.6 (1.3‒1.8)* 4.1 (3.8‒4.4)
Not living alone 0.8 (0.8‒0.9) 1.6 (1.5‒1.8) 1.2 (1.0‒1.4) 3.7 (3.4‒3.9)
95 y
Living alone 0.2 (0.2‒0.3)* 1.2 (1.1‒1.4)* 1.0 (0.8‒1.2) 2.4 (2.2‒2.7)*
Not living alone 0.3 (0.3‒0.3) 1.0 (0.9‒1.1) 0.8 (0.6‒0.9) 2.1 (1.8‒2.3)
Female, age
65 y
Living alone 3.7 (3.4‒4.1)** 4.5 (4.1‒4.9) 5.1 (4.5‒5.7)* 13.3 (12.5‒14.0)
Not living alone 4.8 (4.3‒5.3) 4.1 (3.8‒4.5) 4.0 (3.6‒4.5) 12.9 (12.1‒13.8)
75 y
Living alone 1.7 (1.6‒1.9)** 3.3 (3.1‒3.5) 3.9 (3.5‒4.3)* 8.9 (8.5‒9.4)
Not living alone 2.2 (2.1‒2.5) 3.0 (2.8‒3.2) 3.1 (2.7‒3.4) 8.3 (7.8‒8.8)
85 y
Living alone 0.7 (0.7‒0.8)** 2.3 (2.2‒2.5)* 2.8 (2.5‒3.1)** 5.8 (5.5‒6.2)*
Not living alone 0.9 (0.8‒1.0) 2.0 (1.9‒2.2) 2.2 (1.9‒2.5) 5.2 (4.8‒5.6)
95 y
Living alone 0.3 (0.2‒0.3)* 1.6 (1.4‒1.7)* 1.9 (1.6‒2.2)* 3.7 (3.4‒4.1)*
Not living alone 0.4 (0.3‒0.4) 1.3 (1.2‒1.5) 1.5 (1.2‒1.8) 3.2 (2.9‒3.5)
(C) Dementia medication No formal care Home care Institutional care Total duration
Male, age
65 y
Dementia medication 3.7 (3.3‒4.2)* 3.3 (2.9‒3.7) 2.6 (2.2‒3.1) 9.7 (8.9‒10.5)
No dementia medication 4.6 (4.2‒5.0) 3.4 (3.1‒3.8) 2.4 (2.1‒2.7) 10.4 (9.7‒11.0)
75 y
Dementia medication 1.7 (1.5‒1.9)* 2.4 (2.1‒2.6) 1.9 (1.6‒2.3) 6.0 (5.5‒6.5)
No dementia medication 2.1 (1.9‒2.3) 2.4 (2.3‒2.6) 1.7 (1.6‒2.0) 6.3 (5.9‒6.7)
85 y
Dementia medication 0.7 (0.6‒0.8)* 1.6 (1.4‒1.8) 1.3 (1.1‒1.6) 3.6 (3.3‒4.0)
No dementia medication 0.8 (0.8‒0.9) 1.6 (1.5‒1.8) 1.2 (1.0‒1.4) 3.7 (3.4‒3.9)
95 y
Dementia medication 0.3 (0.2‒0.3) 1.0 (0.9‒1.2) 0.8 (0.7‒1.1) 2.1 (1.9‒2.4)
No dementia medication 0.3 (0.3‒0.4) 1.0 (0.9‒1.1) 0.8 (0.6‒0.9) 2.1 (1.9‒2.3)
Female, age
65 y
Dementia medication 3.9 (3.3‒4.4)* 3.9 (3.5‒4.5) 4.3 (3.6‒5.0) 12.1 (11.0‒13.2)
No dementia medication 4.8 (4.3‒5.3) 4.1 (3.8‒4.5) 4.0 (3.5‒4.6) 12.9 (12.1‒13.8)
(continued on next page)
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Supplementary Table 3 (continued )
(C) Dementia medication No formal care Home care Institutional care Total duration
75 y
Dementia medication 1.8 (1.6‒2.1)* 2.8 (2.5‒3.2) 3.3 (2.8‒3.9) 7.9 (7.3‒8.7)
No dementia medication 2.2 (2.0‒2.5) 3.0 (2.8‒3.2) 3.1 (2.7‒3.5) 8.3 (7.8‒8.9)
85 y
Dementia medication 0.8 (0.6‒0.9)* 2.0 (1.7‒2.2) 2.4 (2.0‒2.8) 5.1 (4.5‒5.6)
No dementia medication 0.9 (0.8‒1.1) 2.0 (1.9‒2.2) 2.2 (1.9‒2.5) 5.2 (4.8‒5.6)
95 y
Dementia medication 0.3 (0.2‒0.3) 1.3 (1.1‒1.5) 1.6 (1.3‒2.0) 3.2 (2.8‒3.7)
No dementia medication 0.4 (0.3‒0.4) 1.3 (1.2‒1.5) 1.5 (1.2‒1.8) 3.2 (2.9‒3.5)
Results are estimated durations of dementia care in years with 95% confidence intervals based on standard deviations of estimated durations for (A) persons with and without
polypharmacy, (B) persons living alone and not living alone, and (C) persons with and without dementia medication. Estimated durations for men and women age 65, 75, 85,
and 95 years at time of diagnosis are shown for the different care states as well as total duration. Estimates for polypharmacy were based on persons without dementia
medication and not living alone, estimates for living situation were based on persons without polypharmacy and without dementia medication, and estimates for dementia
medication were based on persons without polypharmacy and not living alone.
*P < .05 or **P < .001 indicates different duration estimates from estimates of (A) persons without polypharmacy, (B) persons not living alone, and (C) persons without
dementia medication.
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Supplementary Table 4
Estimated Dementia Care Durations in Years by (A) Migration Background and (B) Income, for Men and Women of Different Ages
(A) Migration
Background
No Formal Care Home Care Institutional Care Total Duration
Male, age
65 y
Western 4.2 (3.9‒4.5)** 3.6 (3.4‒3.9) 2.2 (2.0‒2.5)* 10.0 (9.6‒10.5)*
Non‒Western 7.4 (6.2‒8.7) 4.2 (3.4‒5.1) 1.4 (0.9‒2.1) 13.0 (11.1‒15.0)
75 y
Western 1.9 (1.8‒2.0)** 2.6 (2.4‒2.7) 1.6 (1.5‒1.8) 6.1 (5.8‒6.3)*
Non‒Western 3.5 (2.8‒4.2) 3.1 (2.5‒3.8) 1.2 (0.7‒1.7) 7.7 (6.6‒9.1)
85 y
Western 0.7 (0.7‒0.8)** 1.7 (1.6‒1.8) 1.1 (1.0‒1.2) 3.5 (3.4‒3.7)
Non‒Western 1.3 (1.1‒1.7) 2.1 (1.6‒2.6) 0.9 (0.5‒1.4) 4.3 (3.5‒5.3)
95 y
Western 0.2 (0.2‒0.3)* 1.0 (0.9‒1.1) 0.7 (0.6‒0.8) 2.0 (1.8‒2.2)
Non‒Western 0.4 (0.3‒0.6) 1.3 (0.9‒1.7) 0.6 (0.3‒1.0) 2.3 (1.8‒3.0)
Female, age
65 y
Western 4.2 (3.9‒4.5)** 4.7 (4.4‒5.0) 4.1 (3.8‒4.5)* 13.0 (12.4‒13.6)*
Non‒Western 7.6 (6.5‒8.8) 5.7 (4.6‒7.0) 2.6 (1.7‒3.9) 15.9 (14.1‒18.1)
75 y
Western 1.9 (1.8‒2.0)** 3.4 (3.2‒3.5) 3.2 (3.0‒3.4) 8.5 (8.2‒8.8)
Non‒Western 3.7 (3.0‒4.5) 4.3 (3.4‒5.1) 2.2 (1.4‒3.3) 10.1 (8.5‒12.0)
85 y
Western 0.8 (0.7‒0.8)** 2.3 (2.2‒2.4) 2.3 (2.2‒2.5) 5.4 (5.2‒5.6)
Non‒Western 1.5 (1.2‒1.9) 3.0 (2.4‒3.7) 1.7 (1.1‒2.6) 6.2 (5.1‒7.6)
95 y
Western 0.3 (0.2‒0.3)** 1.5 (1.4‒1.6) 1.6 (1.4‒1.8) 3.4 (3.2‒3.6)
Non‒Western 0.5 (0.4‒0.7) 2.0 (1.5‒2.5) 1.2 (0.8‒1.8) 3.8 (3.0‒4.7)
(B) Income No formal care Home care Institutional care Total duration
Male, age
65 y
Higher income 4.9 (4.5‒5.3)** 3.7 (3.5‒4.0) 2.1 (1.9‒2.3) 10.7 (10.2‒11.3)*
Lower income 3.8 (3.5‒4.1) 3.6 (3.3‒3.8) 2.3 (2.0‒2.5) 9.6 (9.1‒10.1)
75 y
Higher income 2.2 (2.0‒2.3)** 2.6 (2.5‒2.8) 1.6 (1.4‒1.7) 6.4 (6.1‒6.6)*
Lower income 1.7 (1.5‒1.8) 2.5 (2.4‒2.7) 1.7 (1.5‒1.8) 5.9 (5.6‒6.1)
85 y
Higher income 0.8 (0.8‒0.9)** 1.7 (1.6‒1.8) 1.1 (1.0‒1.2) 3.6 (3.4‒3.8)
Lower income 0.6 (0.6‒0.7) 1.7 (1.6‒1.8) 1.2 (1.0‒1.3) 3.5 (3.3‒3.6)
95 y
Higher income 0.3 (0.2‒0.3)* 1.0 (0.9.1.1) 0.7 (0.6‒0.8) 2.0 (1.8‒2.2)
Lower income 0.2 (0.2‒0.2) 1.0 (0.9‒1.1) 0.7 (0.6‒0.9) 2.0 (1.8‒2.2)
Female, age
65 y
Higher income 5.0 (4.7‒5.4)** 4.9 (4.6‒5.3) 3.9 (3.5‒4.3) 13.8 (13.1‒14.5)*
Lower income 3.8 (3.5‒4.2) 4.5 (4.2‒4.9) 4.2 (3.8‒4.6) 12.6 (12.0‒13.2)
75 y
Higher income 2.3 (2.2‒2.5)** 3.5 (3.3‒3.7) 3.1 (2.8‒3.4) 8.9 (8.5‒9.3)*
Lower income 1.7 (1.6‒1.8) 3.3 (3.1‒3.4) 3.3 (3.0‒3.5) 8.2 (7.9‒8.5)
85 y
Higher income 0.9 (0.8‒1.0)** 2.4 (2.2‒2.5) 2.3 (2.1‒2.5) 5.6 (5.3‒5.9)
Lower income 0.7 (0.6‒0.7) 2.3 (2.2‒2.4) 2.4 (2.2‒2.6) 5.3 (5.1‒5.5)
95 y
Living alone 0.3 (0.2‒0.3)* 1.6 (1.4‒1.7)* 1.9 (1.6‒2.2)* 3.7 (3.4‒4.1)*
Not living alone 0.4 (0.3‒0.4) 1.3 (1.2‒1.5) 1.5 (1.2‒1.8) 3.2 (2.9‒3.5)
Results are estimated durations of dementia care in years with 95% confidence intervals based on standard deviations of estimated durations for (A) persons with a Western
background and a non‒Western migration background, and (B) persons with a higher and lower income. Estimated durations for men and women age 65, 75, 85, and 95 years
at time of diagnosis are shown for the different care states as well as total duration.
*P < .05 or **P < .001 indicates different duration estimates from estimates of (A) persons with a non‒Western migration background or (B) persons with a lower income.
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